Evidence map›Paper›PMID 26456959›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Plasma miR-940 may serve as a novel biomarker for gastric cancer.

Xin Liu, Ava Kwong, Alan Sihoe, Kent-Man Chu

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Host miRNAs-microbiota interactions in gastric cancer.Journal of translational medicine · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Circulating miR-19a-3p and miR-483-5p as Novel Diagnostic Biomarkers for the Early Diagnosis of Gastric Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  14. Article
  15. Recent advances in gastric cancer early diagnosis.World journal of gastroenterology · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xin LiuDepartment of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
Ava KwongDepartment of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
Alan SihoeDepartment of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
Kent-Man ChuDepartment of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong. chukm@hku.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It was reported that circulating microRNAs could be applied as non-invasive biomarkers for cancer monitoring. The purpose of this study was to identify plasma miRNA that may serve as a novel biomarker for gastric cancer and to evaluate its clinical application. MicroRNA profiles were generated from plasma samples of 5 patients with gastric cancer (GC) versus 5 healthy controls (HC). MicroRNA-940 (miR-940) was one of the most downregulated miRNAs with fold change of 0.164. It was revealed that the expression of miR-940 was downregulated in both the initial set (N = 30, P < 0.0001) and the validation set (N = 80, P < 0.0001) of plasma samples of patients with gastric cancer. The sensitivity was obviously higher than the current biomarkers CEA and CA19-9 (81.25 % vs. 22.54 % and 15.71 %). MiR-940 was also significantly downregulated in gastric cancer tissue samples (N = 34, P = 0.0015), as well as in cancer cell lines (N = 7). Importantly, miR-940 was significantly highly expressed in stomach tissue samples than in other types of tissue samples including the liver, breast, thyroid, and lung. Moreover, there was a trend of lower expression of miR-940 from early to advanced stage of gastric cancer. Target prediction suggested that miR-940 regulated cell signaling including NF-κB and Wnt/β-catenin, as well as pathways of cell communication and adhesion. These pathways play critical roles in gastric cancer initiation and progression. It is the first report that miR-940 may mainly express in the stomach. Downregulation of plasma miR-940 may serve as a novel biomarker for detection of gastric cancer.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBiomarkers, TumorCell Line, TumorDown-RegulationFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedOligonucleotide Array Sequence AnalysisReverse Transcriptase Polymerase Chain ReactionStomach NeoplasmsBiomarkers, TumorMicroRNAsMIRN940 microRNA, humanBiomarkerDiagnosisGastric cancermiR-940Plasma

Identifiers

PMID26456959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.